User login
High-impact presentations on chronic kidney disease from the American Society of Nephrology (ASN) 2023 meeting are discussed by Dr Matthew Weir from the University of Maryland School of Medicine in Baltimore.
He starts with the results of the PROTECT and DUPLEX trials, in which sparsentan was compared with irbesartan in immunoglobulin A nephropathy and focal segmental glomerulosclerosis, respectively. In both studies, sparsentan resulted in greater reduction in albuminuria compared with irbesartan but with no significant differences in estimated glomerular filtration rate (GFR).
He also talks about the AYAME study of bardoxolone methyl in diabetic kidney disease, which was intended to examine the percentage of patients reaching a 30% reduction in GFR or end-stage renal disease. Bardoxolone slowed the reduction in the GFR but showed no benefit in reducing end-stage renal disease.
Next, Dr Weir reports the results from the ALCHEMIST trial on spironolactone in patients with chronic hemodialysis, which showed a reduction in hospitalization rates for heart failure in the spironolactone group but no improvement in mortality.
Finally, he discusses two studies looking at combining newer therapies on a background of traditional ones that suggest a potential for reducing albuminuria.
--
Matthew R. Weir, MD, Professor and Chief, Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Lutherville-Timonium, Maryland; Professor and Chief, Division of Nephrology, Department of Medicine, University of Maryland Medical Center, Baltimore, Maryland
Matthew R. Weir, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AstraZeneca; Bayer; NovoNordisk; Boehringer-Ingelheim; Johnson & Johnson; CSL Vifor
High-impact presentations on chronic kidney disease from the American Society of Nephrology (ASN) 2023 meeting are discussed by Dr Matthew Weir from the University of Maryland School of Medicine in Baltimore.
He starts with the results of the PROTECT and DUPLEX trials, in which sparsentan was compared with irbesartan in immunoglobulin A nephropathy and focal segmental glomerulosclerosis, respectively. In both studies, sparsentan resulted in greater reduction in albuminuria compared with irbesartan but with no significant differences in estimated glomerular filtration rate (GFR).
He also talks about the AYAME study of bardoxolone methyl in diabetic kidney disease, which was intended to examine the percentage of patients reaching a 30% reduction in GFR or end-stage renal disease. Bardoxolone slowed the reduction in the GFR but showed no benefit in reducing end-stage renal disease.
Next, Dr Weir reports the results from the ALCHEMIST trial on spironolactone in patients with chronic hemodialysis, which showed a reduction in hospitalization rates for heart failure in the spironolactone group but no improvement in mortality.
Finally, he discusses two studies looking at combining newer therapies on a background of traditional ones that suggest a potential for reducing albuminuria.
--
Matthew R. Weir, MD, Professor and Chief, Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Lutherville-Timonium, Maryland; Professor and Chief, Division of Nephrology, Department of Medicine, University of Maryland Medical Center, Baltimore, Maryland
Matthew R. Weir, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AstraZeneca; Bayer; NovoNordisk; Boehringer-Ingelheim; Johnson & Johnson; CSL Vifor
High-impact presentations on chronic kidney disease from the American Society of Nephrology (ASN) 2023 meeting are discussed by Dr Matthew Weir from the University of Maryland School of Medicine in Baltimore.
He starts with the results of the PROTECT and DUPLEX trials, in which sparsentan was compared with irbesartan in immunoglobulin A nephropathy and focal segmental glomerulosclerosis, respectively. In both studies, sparsentan resulted in greater reduction in albuminuria compared with irbesartan but with no significant differences in estimated glomerular filtration rate (GFR).
He also talks about the AYAME study of bardoxolone methyl in diabetic kidney disease, which was intended to examine the percentage of patients reaching a 30% reduction in GFR or end-stage renal disease. Bardoxolone slowed the reduction in the GFR but showed no benefit in reducing end-stage renal disease.
Next, Dr Weir reports the results from the ALCHEMIST trial on spironolactone in patients with chronic hemodialysis, which showed a reduction in hospitalization rates for heart failure in the spironolactone group but no improvement in mortality.
Finally, he discusses two studies looking at combining newer therapies on a background of traditional ones that suggest a potential for reducing albuminuria.
--
Matthew R. Weir, MD, Professor and Chief, Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Lutherville-Timonium, Maryland; Professor and Chief, Division of Nephrology, Department of Medicine, University of Maryland Medical Center, Baltimore, Maryland
Matthew R. Weir, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AstraZeneca; Bayer; NovoNordisk; Boehringer-Ingelheim; Johnson & Johnson; CSL Vifor
